Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 5S ribosomal pseudogene 326 (RNA5SP326), is a member of the large family of processed and unprocessed pseudogenes in the human genome. It is homologous to 5S ribosomal RNA genes but has acquired mutations that make it nonfunctional for ribosome assembly or protein synthesis. Pseudogenes like RNA5SP326 typically arise through gene duplication or retrotransposition events and do not produce functional RNA or protein products. While most pseudogenes are traditionally considered "genomic fossils" without biological function, recent research indicates that some may exert regulatory effects on gene expression via RNA-mediated mechanisms (such as competing endogenous RNA or antisense regulation). However, there is no literature supporting any direct biological, therapeutic, or drug-target role for RNA5SP326 itself, and it is not recognized as a classical, actionable drug target such as a receptor, enzyme, transporter, or transcription factor. Consequently, RNA5SP326 is generally not included in drug discovery pipelines or as a validated biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 5S ribosomal pseudogene 326 (RNA5SP326).